COVID-19 vaccine candidates and vaccine development platforms available worldwide
- Author:
Duman NILGUN
1
;
ALzaidi ZAHRAA
;
Aynekin BUSRA
;
Taskin DUYGU
;
Demirors BUSRA
;
Yildirim ABDULBAKI
;
Sahin Olcay IZEM
;
Bilgili FAIK
;
Turanli Tahir EDA
;
Beccari TOMMASO
;
Bertelli MATTEO
;
Dundar MUNIS
Author Information
1. Department of Medical Genetics,Dragos Hospital Istanbul,Bezmialem Vakif University,Istanbul,34854,Turkey
- Keywords:
COVID-19 vaccine;
Vaccine development platform;
Coronavirus outbreak;
SARS-CoV-2 variants;
Treatment
- From:
Journal of Pharmaceutical Analysis
2021;11(6):675-682
- CountryChina
- Language:Chinese
-
Abstract:
The pandemic caused by the worldwide spread of the coronavirus,which first appeared in 2019,has been named coronavirus disease 19 (COVID-19).More than 4.5 million deaths have been recorded due to the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),according to the World Health Organization.COVID-19 Dashboard in September 2021.Apart from the wildtype,other variations have been successfully transmitted early in the outbreak although they were not discovered until March 2020.Modifications in the SARS-CoV-2 genetic material,such as mutation and recombi-nation,have the ability to modify the viral life span,along with transitivity,cellular tropism,and symptom severity.Several processes are involved in introducing novel vaccines to the population,including vaccine manufacturing,preclinical studies,Food and Drug Administration permission or cer-tification,processing,and marketing.COVID-19 vaccine candidates have been developed by a number of public and private groups employing a variety of strategies,such as RNA,DNA,protein,and viral vectored vaccines.This comprehensive review,which included the most subsequent evidence on unique features of SARS-CoV-2 and the associated morbidity and mortality,was carried out using a systematic search of recent online databases in order to generate useful knowledge about the COVID-19 updated versions and their consequences on the disease symptoms and vaccine development.
